Modafinil, Sleep Architecture and Cocaine Relapse
This study is currently recruiting participants.
Verified July 2012 by Yale University
Sponsor:
Yale University
Information provided by (Responsible Party):
Yale University
ClinicalTrials.gov Identifier:
NCT01137396
First received: June 3, 2010
Last updated: July 19, 2012
Last verified: July 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The medication modafinil has been shown to reduce cocaine use in some cocaine users. The investigators have shown that modafinil taken in the morning improves sleep in chronic cocaine users. The investigators hypothesize that the beneficial effects of modafinil in reducing cocaine use may be related to specific effects modafinil has on sleep. This study will measure sleep and cocaine use in cocaine dependent persons who are trying to stop using cocaine, and will test the connection between modafinil's effects on sleep and cocaine use.
| Condition | Intervention | Phase |
|---|---|---|
|
Cocaine Dependence |
Drug: Modafinil Behavioral: Cognitive Behavioral Therapy |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Modafinil, Sleep Architecture and Cocaine Relapse |
Resource links provided by NLM:
Further study details as provided by Yale University:
Primary Outcome Measures:
- Number of cocaine-free urines [ Time Frame: 3x/week ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Polysomnographically measured sleep [ Time Frame: 5 times over 8 weeks ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 120 |
| Study Start Date: | April 2010 |
| Estimated Study Completion Date: | February 2015 |
| Estimated Primary Completion Date: | February 2015 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Modafinil |
Drug: Modafinil
Modafinil 400mg PO QDaily following up-titration for ~8weeks
Behavioral: Cognitive Behavioral Therapy
Once weekly cognitive behavioral therapy for cocaine dependence
|
| Placebo Comparator: Placebo |
Behavioral: Cognitive Behavioral Therapy
Once weekly cognitive behavioral therapy for cocaine dependence
|
Eligibility| Ages Eligible for Study: | 25 Years to 50 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- 25-50 years of age;
- voluntary, written, informed consent;
- seeking but not currently enrolled in treatment for cocaine use;
- self-reported, current use of cocaine by smoked or intravenous route at least one time each week in the past month, with ≥1g used within a single 24-hour period and ≥3g used in the month;
- positive urine test for cocaine (benzoylecognine) at the time of screening and study start
- dependence on cocaine in the past year as measured by a score ≥ 3 on the Severity of Dependence Scale(Kaye and Darke, 2002);
- chronic use in the past year as determined by self-reported use in at least 9 of the past 12 months;
- lifetime diagnosis of cocaine dependence with a duration of at least 2 years as determined by the Structured Clinical Interview for DSM-IV (SCID).
Exclusion Criteria:
- evidence of any neurological condition or a chronic medical condition including diabetes, cardiovascular disease or history of cardiac problems, HIV-seropositivity, liver disease, hypertension, asthma requiring daily medication, dementia, movement disorder, history of head trauma with loss of consciousness, sleep apnea, narcolepsy, restless leg syndrome, periodic limb movement disorder, REM sleep disorder, pharmacological treatment for insomnia of any type within the past 6 months, glaucoma, severe respiratory insufficiency, seizure disorder, or if in the past three months they have taken any medications that affect sleep, or are currently taking any regularly dosed prescription medication or any prn medication that is used on average more than 1x/week
- evidence of chronic sleep disorder including sleep apnea, narcolepsy, periodic limb movement disorder, restless leg syndrome as determined by medical history, Sleep Disorders Questionnaire(Douglass, 1994), or by polysomnography (following enrollment)
- current dependence on any drugs other than cocaine or nicotine or lifetime dependence on alcohol, benzodiazepines, or opiates, or any non-substance related Axis I disorder as determined by SCID
- current use of alcohol in excess of 3x/week AND 21 standard drinks/week in the past month or non-zero breathalyzer at screening or study start
- current use of cannabis in the past month
- positive urine toxicology test for opiates, methadone, amphetamines, barbiturates, benzodiazepines, PCP, methaquolone, and propoxyphene at the time of screening or positive test for any of those listed plus cannabis at the time of study start
- pregnancy as determined by serum β-HCG at screening or lactating per report
- females: unwillingness to use barrier contraceptives during sexual intercourse for the duration of the study
- known hypersensitivity to modafinil.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01137396
Contacts
| Contact: Erica Forselius, B.A. | 203-974-7545 | erica.forselius@yale.edu |
| Contact: Jennifer Vollmer, B.A. | 203-974-7545 | jennifer.vollmer@yale.edu |
Locations
| United States, Connecticut | |
| Connecticut Mental Health Center | Recruiting |
| New Haven, Connecticut, United States, 06519 | |
Sponsors and Collaborators
Yale University
Investigators
| Principal Investigator: | Peter Morgan, MD, PhD | Yale University |
More Information
No publications provided
| Responsible Party: | Yale University |
| ClinicalTrials.gov Identifier: | NCT01137396 History of Changes |
| Other Study ID Numbers: | 0911005989, DA011744-08 |
| Study First Received: | June 3, 2010 |
| Last Updated: | July 19, 2012 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Cocaine-Related Disorders Substance-Related Disorders Mental Disorders Cocaine Modafinil Vasoconstrictor Agents Cardiovascular Agents Therapeutic Uses Pharmacologic Actions Dopamine Uptake Inhibitors Dopamine Agents Neurotransmitter Agents |
Molecular Mechanisms of Pharmacological Action Neurotransmitter Uptake Inhibitors Physiological Effects of Drugs Anesthetics, Local Anesthetics Central Nervous System Depressants Sensory System Agents Peripheral Nervous System Agents Central Nervous System Agents Central Nervous System Stimulants Neuroprotective Agents Protective Agents |
ClinicalTrials.gov processed this record on May 16, 2013